The prescription drugs dapagliflozin (Forxiga) and canagliflozin (Invokana), used to treat diabetes, are being reviewed by Health Canada in connection with the risk of ketoacidosis, a serious diabetes complication that leads to high levels of blood acids (ketones.)
These drugs are in a class known as SGLT2 (sodium-glucose cotransporter-2) inhibitors and are approved in Canada for use in patients that suffer with type-2 diabetes. They work to improve sugar levels, along with exercise and a healthy diet.
Health Canada’s adverse reaction database identified one report of diabetic ketoacidosis that involved the hospitalization of a patient, 56, taking an SGLT2 inhibitor. Further investigating is needed because the patient was also taking other medications.
At this time it is yet to be decided if there will be changes to the prescribing information for SGLT2 drugs. While the investigation is ongoing, Health Canada is advising of the potential risk and encourages reporting of any adverse reactions to the agency.
What patients should do
If you currently take an SGLT2 and have any questions or concerns, you should talk to your medical doctor.
Do not discontinue use of Forxiga or Invokana without first consulting your medical doctor.
The symptoms of ketoacidosis include abdominal pain, loss of appetite, confusion, difficulty breathing, thirsty, vomiting and nausea. If you think you are experiencing any of these symptoms while on this medical, seek urgent medical attention.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.